Embed Size (px)
Citation preview
Cancer ProgramAnnual Report
CANCER REGISTRY STATISTICS
2014 annual report
Sue KilbourneDirector of Cancer Services, Asante Rogue Regional Medical CenterCancer Program Administrator
Juan M. Castillo, MD, FACSChairman of the Asante Rogue Regional Medical Center Cancer Committee
2At Asante Rogue Regional, we believe that cancer survivorship begins at diagnosis. We offer people with cancer and their families the most effective diagnostic services, treatment, information and support possible. Because high-quality care and excellent patient outcomes are the top priority, our staff and physician partners continuously monitor, measure and work to improve the quality of our leading-edge services.
The American College of Surgeons Commission on Cancer establishes standards for accreditation to ensure high-quality, multidisciplinary and comprehensive cancer care delivery. Asante Rogue Regional has an accredited cancer program. This prestigious national distinction is awarded to cancer treatment facilities that meet the highest-quality requirements established
by the Commission on Cancer. These standards focus on cancer prevention, early diagnosis, optimal treatment, rehabilitation, surveillance for recurrent disease, support services and end-of-life care. Accreditation also considers a cancer program’s ongoing participation in research and the extent of outreach and education offered in the community.
This year's annual report outlines our efforts to meet or exceed the cancer care standards established by the commission. It is our honor to share this report outlining Asante Rogue Regional’s continuing work to provide our patients with the best that medicine has to offer, and we remain dedicated to treating cancer and restoring health and wellness for each of our extraordinary patients.
The Asante Rogue Regional Medical Center Cancer Committee provides comprehensive multidisciplinary cancer care for the southern Oregon and northern California region. An accredited program of the American College of Surgeons, Asante Cancer Services is committed to providing state-of-the-art care. The treatment of cancer is continuously evolving, and as a committee we are committed to improving cancer care services in our region.
In 2014 we focused on updating our inpatient services to provide more opportunity for educating our oncology patients and their families. Cancer treatment has become a multidisciplinary practice that includes not only multiple physician specialists but also dietitians,
physical therapists and oncology nurses, which for some patients can be overwhelming. We feel that providing education in multiple formats alleviates some of that confusion and stress.
Our community outreach projects for 2014 focused on lung cancer prevention and breast cancer screening. We also implemented a new telemedicine program in partnership with Oregon Health & Science University to provide genetic counseling with associate professor Jone Sampson, MD. This program has been quite successful, and we have already expanded it to provide more clinic days for our patients. I am proud of our accomplishments in 2014 and hope that you find our annual report both informative and educational.
Cancer Committee
The Asante Rogue Regional Cancer Committee is composed of physicians from varying specialties and other health care professionals active in oncology services. The Cancer Committee oversees our cancer program and strives to enhance the quality of care we provide to all of our patients.
3
Juan Castillo, MD, FACS Jay Beckstead, MD Surgery PathologyCommittee ChairmanCancer Liaison Physician Jere L. Sandefur, MD Radiation OncologyCraig N. Haveman, MD Radiation Oncology Chad Ringger, MD Diagnostic RadiologyNancy O’Neal, MD, FACS Surgery Aleksandra Sander, MD Hematology/OncologyKristina Darlington, DO Diagnostic Radiology E Bruce Barrows, MD UrologyTheodore Robnett, MD Radiation Oncology Jack Lewis, MD UrologyAlison Savage, MD Hematology/Oncology Amanda Foster Cancer Registry Quality CoordinatorSue Kilbourne Cancer Program Administrator Sharon Krische Palliative Care CoordinatorRichard DeWitt Swallowing, Speech Rehabilitation Gail Kessler Psychosocial Services CoordinatorMelanie Dines Breast Health/Oncology Navigator Loretta Petersen Performance ImprovementJason Shaw Cancer Conference Coordinator Charlie Johnson American Cancer SocietyMaya Hawkins-Carter Clinical Research Coordinator Sandra Radtke Psychosocial ServicesAdrienne Goldberg Palliative Care Jennifer Johnson Cancer RegistrySteve Archer Quality Coordinator
Standard 1.5 | Cancer program annual goals
Annual goals provide direction for strategic planning of our cancer program activities. This year our program focused on educating our patients and their families regardless of the care setting. Whether newly diagnosed, currently undergoing treatment or living as survivors, patients and families want information and education about available resources, as well as what they may expect in other care settings. Having the appropriate education helps decrease anxiety and confusion, especially when patients are treated in multiple settings.
4
Consistent educational materials provided in a variety of forms (electronic, printed, verbal and video) often help patients retain critical information, which may positively influence patient outcomes and experiences.
With this in mind, over the past year we did the following:
■ Added a new chemotherapy educational video to the hospitalwide TV network
■ Removed outdated educational books and brochures from the inpatient unit, the Dubs cancer resource center and the outpatient infusion areas
■ Updated unit-specific patient information
■ Added current brochures from other departments’ cancer-related services to information available in our cancer clinic areas (radiation oncology, infusion services and inpatient oncology)
■ Updated the website with current information about Cancer Services
PINK Breast
BURGUNDY Multi Myeloma
NAVY BLUE Colon
AMBERAppendix
LIME Lymphoma
GREYBrain
YELLOWBladder
BURGUNDY/
Head/Neck
PURPLEPancreatic
LAVENDERAll
LIGHT ORANGE
Kidney
TEAL Ovarian
GREENLiver
PERIWINKLE Stomach
GOLDChildhood
ORCHID Testicular
ORANGELeukemia
PEACH Uterine
BLACKMelanoma
ZEBRA Carcinoid
LungBone
Sarcoma
WHITE
WHITELIGHTEST YELLOW
LIGHT YELLOW
Cancer Awareness Ribbon ColorsAsante Cancer Services
15ONCR007
Gynecologic Cancer
Support Group
Third Monday of each month12:30 to 2 p.m.
Asante Rogue Regional Medical Center
First Floor, Dubs Library
Support • Empowerment
Education • Advocacy
Standard 4.1 | Prevention programs
Each year the Cancer Committee provides at least one cancer prevention program to meet the needs of the community.
5
Breath for Life
Start now—it is the perfect
time to quit tobacco
C E L E B R A T E
Cancer Survivors and their Families
Ride for a Reason Friday, May 29
at the Central Point Wild Rogue Pro Rodeo
Join us >
In Oregon more people die from lung cancer than any other type. Oregon is 18th in the nation for the prevalence of smokers. The number of adult smokers in Oregon is 19.7 percent, compared with the national average of 21.1 percent. A recent state health report card gave Oregon an A for passing laws for smoke-free bars, restaurants and workplaces. But in all other measures, Oregon received D’s and F’s. Oregon’s anti-smoking media ads rank only 38th in the nation. Total dollars spent on anti-tobacco ads received an F — far below the national average. The Oregon cigarette tax ranks 29th.
In an effort to support the community in becoming tobacco-free, Asante Rogue Regional offers a tobacco-cessation program called Breath for Life. This comprehensive program is available to Asante employees and to other employers in both Jackson and Josephine counties. Participants receive a 20 percent discount on over-the-counter pharmacotherapy items through Rogue Valley Rx, as well
as one-on-one counseling or group support sessions with a Freedom From Smoking facilitator.
In June our cancer program hosted a Cancer Survivors Day in conjunction with the Wild Rogue Pro Rodeo. The focus was on lung cancer awareness and preventive measures. The Asante Rogue Regional respiratory therapist answered questions and display diseased lungs for a dramatic response, as well as conducted a drawing for a guided fishing trip. During the three-hour event, 525 people visited the booth.
Oregon ranks 6th in the nation for incidences of melanoma, the deadliest form of skin cancer.
In an effort to raise awareness about the prevention of skin cancer, our Relay for Life team distributed free sunscreen and educational materials focused on protecting children from overexposure to sun.
Standard 4.2 | Screening programs
Breast cancer is the most commonly diagnosed cancer. One in nine women will be diagnosed with this disease.
6
Asante Rogue Regional’s breast health navigator, Melanie Dines, worked with Angela Freeman, community program manager of Southern Oregon SCREEN, to educate 1,320 women about the importance of breast self-examinations. SCREEN is an outreach education program funded through Oregon and SW Washington Susan G. Komen for the Cure. The program seeks to ensure that all people, regardless of race, income, geographic location or insurance coverage, have access to screening, support services and high-quality breast care treatment.
Free clinical breast exams and screenings were held in October, and 80 percent of the participants qualified for free screening mammogram vouchers. No breast malignancies were diagnosed among the women who attended. Asante Rogue Regional also offers screening mammograms through a voucher program. Of the 98 vouchers issued, 73 were redeemed; 15 percent of the participants were Hispanic, 1 percent were Chinese and the remaining were white. Three women had additional diagnostic imaging.
* This is not a mammogram screening.
* This is not a mammogram screening.
Health care professionals will volunteer their time to
conduct free physical breast exams for this important
women’s health screening event.* Learn about
resources for no cost or low cost mammograms. Health care professionals will volunteer their time to
conduct free physical breast exams for this important
women’s health screening event.* Learn about
resources for no cost or low cost mammograms.
Free Clinical Breast ExamsFree Clinical Breast Exams
asante.org
asante.org
GRANTS PASSTuesday, Oct. 27 • 3 to 5 p.m. Women’s Health Center
of Southern Oregon, PC1075 SW Grandview Avenue
Suite 200Call to register: (541) 955-5446Presented by Women’s Health
Center of Southern Oregon, PC
in association with Asante Women’s Imaging
GRANTS PASSTuesday, Oct. 27 • 3 to 5 p.m. Women’s Health Center
of Southern Oregon, PC1075 SW Grandview Avenue
Suite 200Call to register: (541) 955-5446Presented by Women’s Health
Center of Southern Oregon, PC
in association with Asante Women’s Imaging
MEDFORDThursday, Oct. 29 • 4 to 6 p.m.
Medford Women’s Clinic 3170 State StreetCall to register: (541) 789-6165
Presented by Medford Women’s
Clinic in association with Asante
Imaging—Women’s Services
MEDFORDThursday, Oct. 29 • 4 to 6 p.m.
Medford Women’s Clinic 3170 State StreetCall to register: (541) 789-6165
Presented by Medford Women’s
Clinic in association with Asante
Imaging—Women’s Services
15AI027
15AI027
• BreastcanceristheNo.2causeofdeathinwomenoverall.
• 1in8womeninthePacificNorthwestwillbediagnosedwithbreastcancerinherlifetime.
• 9outof10breastcancerpatientshavenofamilyhistoryofbreastcancer.
…becauseearlydetectionsaveslives.Don’twait,scheduleyourstoday!
Asante joins the American College of Radiology and the Society of Breast Imaging
in recommending that women age 40 and older should have a screening mammogram
every year for as long as they are in good health.
If you have questions about mammograms, please contact your provider.
the guidelines
are simple
Whyyouneedamammogram…
Standard 2.3 | Risk assessment and genetic counseling
7
The purposes of genetic counseling are to educate patients about their chances of developing cancers, help them understand personal meaning from genetic information and empower them to make educated, informed decisions about genetic testing, cancer screening and cancer prevention. Identifying patients at increased risk of developing cancer because of a known hereditary cancer syndrome can have a dramatic effect on early detection and outcome.
Last year we established a telemedicine genetics clinic in collaboration with the Department of Molecular and Medical Genetics at
Oregon Health & Science University in Portland. This telemedicine network enables real-time interactive consultations, bringing to Asante Rogue Regional the expertise of OHSU physician geneticist Jone Sampson, MD. This clinic has been very well-received.
This year, as a study of quality, we looked at data collected from the clinic for the previous year. We are pleased to report that 78 people were seen in our genetic clinic; 44 were tested after genetic counseling, and nine had positive genetic mutations that required follow-up.
Cancer risk assessment and genetic counseling identify and advise people at risk for familial or hereditary cancer syndromes.
CancerGenetic Counseling
Now Available at Asante
Rogue Regional
Cancer Genetic Counseling | 2825 East Barne� Road, Medford, Oregon 97504
asante.org
��RRMC��������-RRMC-�����������/��/���
CancerGenetic Counseling
Standard 4.8 | Quality improvements
This year one of our quality improvements focused on improving the efficiency of chemotherapy administration for patients admitted to the hospital to receive chemotherapy over several days.
8
Patient Handbook
Infusion Services
In a quality study, we had looked for gaps in the current process that potentially could cause avoidable delays in the administration of chemotherapy. Such delays could affect patients’ length of stay, which could put them at higher risk of infection, increase costs for both hospital and patient and inconvenience patients and their families.
The results of the study showed a variety of issues that could delay the administration of chemotherapy, which involved nursing, pharmacy and coordination of care.
As a result of the study, we implemented changes that shortened the time some patients had to stay in the hospital. For example, a simple change of infusing compatible nausea drugs simultaneously instead of separately resulted in a decrease in infusion time of one to two hours each day. This allowed some patients to be discharged a day earlier compared with previous treatments.
Standard 1.6 | Cancer Registry report
The Cancer Registry is a computerized database that includes suspense cases, abstracted data, follow-up data and statistical report capabilities.
The Registry met the National Cancer Data Base call for data deadline for 2014. The timetable was met, and all cases were submitted error-free. Oregon State Cancer Registry reporting requirements were met, as well.
In addition to supporting the joint Cancer Committee meetings, Registry personnel assisted in Asante’s Community Health Needs Assessment for cancer, which used Registry data as well as patient care evaluations on breast cancer for the past five years.
Annual follow-up rates of patients met standards at an average of 90 percent back to our reference date of 2004 and 91 percent for the most recent five years of accessions.
9
The Asante Rogue Regional Cancer Registry is an essential component of the cancer program.
Asante Rogue Regional Medical Centertop 15 sites treated
Cases diagnosed January 1 to December 31, 2014
123456789
101112131415
16314152443826252424221917171611
Breast (female)LungColonProstateUrinary bladderRectumKidneyMelanoma skinLip oral cavity pharynxNon-Hodgkin’s LymphomaBenign brain and CNSBrain and nervous systemCorpus uteriThyroidStomach
Diagnostic site Number of cases
Standard 1.6 | Cancer Registry report
10
Asante Rogue Regional analytic cancer cases 2005–2014
751
890 892
981 973 954
1094
994
1039
933
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Year of Diagnosis
Num
ber o
f Cases
Asante Rogue Regional Medical Center Analy:c Cancer Cases 2005 -‐ 2014
1,200
1,100
1,000
900
800
700
600
500
400
300
200
100
0
890 892
981 973954
1,094
994
1,039
933
751
Num
ber o
f cas
es
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Year of diagnosis
Standard 1.6 | Cancer Registry report
11
Asante Rogue Regional annual frequency of diagnosis: SEER diagnostic groups10-year review: Cases diagnosed 2005–2014
Diagnostic group 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Totals %
Head and neck 30 34 27 24 28 25 39 35 35 27 304 3.20Digestive 129 169 142 162 175 180 196 204 206 173 1736 18.27Respiratory 151 172 163 179 194 179 200 199 186 194 1817 19.12Bones and joints 1 1 4 2 1 1 — — — 2 12 0.13Soft tissue 5 3 3 5 4 6 7 7 5 2 47 0.50Skin 16 20 16 12 16 14 29 20 11 26 180 1.89Breast 188 181 199 218 207 191 265 182 194 201 2026 21.32Female genital 30 45 55 54 50 44 46 42 40 40 446 4.69Male genital 61 78 73 70 63 71 50 48 91 54 659 6.94Urinary 20 23 56 68 59 71 77 70 88 81 613 6.45Eye/orbit — — — — — — — — — — — —Brain/CNS 32 30 32 34 33 21 34 40 42 39 337 3.55Endocrine 21 37 37 45 35 45 43 47 32 24 366 3.85Lymphoma 36 43 49 54 55 46 48 44 51 37 463 4.87Myeloma 11 14 5 10 9 11 10 12 11 8 101 1.06Leukemia 8 19 15 17 19 19 19 17 16 9 158 1.66Mesothelioma 3 2 2 2 — 7 7 3 5 2 33 0.35Kaposi sarcoma — — — — — — — — — — — —Other 9 19 14 26 26 23 23 24 28 13 205 2.16Totals 751 890 892 982 974 954 1093 994 1041 932 9503 100.00
ASANTE ROGUE REGIONAL MEDICAL CENTERANNUAL FREQUENCY OF DIAGNOSIS: SEER DIAGNOSTIC GROUPS
10 Year Review: Cases Diagnosed 2005-‐2014
0
50
100
150
200
250
300
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Head and neck
DigesTve
Respiratory
Bones and joints
SoU Tssue
Skin
Breast
Female genital
Male genital
Urinary
Eye/orbit
Brain/CNS
Endocrine 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
300
250
200
150
100
50
0
Head and neck
Digestive
Respiratory
Bones and joints
Soft tissue
Skin
Breast
Female genital
Male genital
Urinary
Eye/orbit
Brain/CNS
Endocrine
Standard 1.6 | Cancer Registry report
12
Asante Rogue Regional Site, gender and collaborative stage data933 cases diagnosed January 1 to December 31, 2014
Male Female 0 1 2 3 4 NA UNK
ORAL CAVITY AND PHARYNX 27 2.9 Lip — — — — — — — — — — — Tongue 10 1.1 7 3 — 2 1 — 7 — — Salivary gland 6 0.6 5 1 — — 1 1 4 — — Floor of mouth — — — — — — — — — — — Gum and other mouth 2 0.2 1 1 — — — — 1 — 1 Nasopharynx 5 0.5 4 1 — — 1 — 4 — — Tonsil 1 0.1 1 — — — — 1 — — — Oropharynx 2 0.2 1 1 — — — — 1 — 1 Hypopharynx 1 0.1 1 — — — — 1 — — — Other oral cavity and pharynx — — — — — — — — — — —DIGESTIVE SYSTEM 173 18.6 Esophagus 11 1.2 9 2 — 4 — 2 4 — 1 Stomach 14 1.5 7 7 — 2 1 4 4 — 3 Small intestine 2 0.2 1 1 — — — 1 1 — — Colon and rectum 87 9.3 43 44 — 18 21 30 16 — 2 Colon excluding rectum 56 6.0 27 29 — 8 15 21 12 — — Cecum 8 0.9 3 5 — 1 1 5 1 — — Appendix 3 0.3 3 — — — 1 — 2 — — Ascending colon 10 1.1 3 7 — 1 3 3 3 — — Hepatic flexure 3 0.3 2 1 — — — 3 — — — Transverse colon 14 1.5 7 7 — 2 5 5 2 — — Splenic flexure — — — — — — — — — — — Descending colon 3 0.3 1 2 — 1 1 1 — — — Sigmoid colon 13 1.4 6 7 — 3 4 3 3 — — Large intestine, NOS 2 0.2 2 — — — — 1 1 — — Rectum and rectosigmoid junction 31 3.3 16 15 — 10 6 9 4 — 2 Rectosigmoid junction* 5 0.5 2 3 — 1 — 4 — — — Rectum 22 2.4 12 10 — 8 4 4 4 — 2 Anus, anal canal and anorectum 4 0.4 2 2 — 1 2 1 — — — Liver and intrahepatic bile duct 26 2.8 17 9 — 8 3 6 6 1 2 Liver 18 1.9 12 6 — 5 1 6 5 1 — Intrahepatic bile duct 3 0.3 2 1 — — 1 — — — 2 Gallbladder 2 0.2 — 2 — 1 — — 1 — — Other biliary 3 0.3 3 — — 2 1 — — — — Pancreas 26 2.8 15 11 — 2 7 4 11 — 2 Retroperitoneum — — — — — — — — — — — Peritoneum, omentum and mesentery — — — — — — — — — — — Other digestive organs 7 0.8 5 2 — — — — — 7 —RESPIRATORY SYSTEM 194 20.8 Nose, nasal cavity and middle ear — — — — — — — — — — — Larynx 3 0.3 3 — — 1 — — 2 — — Pleura — — — — — — — — — — — Lung and bronchus 191 20.5 100 91 — 57 28 35 70 — 1 Non–small cell 172 18.5 91 81 — 56 27 28 60 — 1 Small cell 14 1.5 6 8 — — 1 7 6 — — Other lung 5 0.5 3 2 — 1 — — 4 — — Trachea — — — — — — — — — — — Mediastinum and other respiratory — — — — — — — — — — —BONES AND JOINTS 2 0.2SOFT TISSUE INCLUDING HEART 2 0.2
Male Female 0 1 2 3 4 NA UNK SKIN 26 2.8 Melanoma of the skin 25 2.7 13 12 4 7 5 4 4 — 1
ASANTE ROGUE REGIONAL MEDICAL CENTERSITE, GENDER, AND COLLABORATIVE STAGE TABLE
933 Cases Diagnosed January 1-‐ December 31, 2014
NCI diagnosis group Total % Gender Collaborative stage group
Collaborative stage groupNCI diagnosis group Total %
Gender
continued on next page
*One additional rectosigmoid case (Stage 2) not coded in the table due to transsexual status.
Standard 1.6 | Cancer Registry report
13
Asante Rogue Regional Site, gender and collaborative stage data933 cases diagnosed January 1 to December 31, 2014
Male Female 0 1 2 3 4 NA UNK
ORAL CAVITY AND PHARYNX 27 2.9 Lip — — — — — — — — — — — Tongue 10 1.1 7 3 — 2 1 — 7 — — Salivary gland 6 0.6 5 1 — — 1 1 4 — — Floor of mouth — — — — — — — — — — — Gum and other mouth 2 0.2 1 1 — — — — 1 — 1 Nasopharynx 5 0.5 4 1 — — 1 — 4 — — Tonsil 1 0.1 1 — — — — 1 — — — Oropharynx 2 0.2 1 1 — — — — 1 — 1 Hypopharynx 1 0.1 1 — — — — 1 — — — Other oral cavity and pharynx — — — — — — — — — — —DIGESTIVE SYSTEM 173 18.6 Esophagus 11 1.2 9 2 — 4 — 2 4 — 1 Stomach 14 1.5 7 7 — 2 1 4 4 — 3 Small intestine 2 0.2 1 1 — — — 1 1 — — Colon and rectum 87 9.3 43 44 — 18 21 30 16 — 2 Colon excluding rectum 56 6.0 27 29 — 8 15 21 12 — — Cecum 8 0.9 3 5 — 1 1 5 1 — — Appendix 3 0.3 3 — — — 1 — 2 — — Ascending colon 10 1.1 3 7 — 1 3 3 3 — — Hepatic flexure 3 0.3 2 1 — — — 3 — — — Transverse colon 14 1.5 7 7 — 2 5 5 2 — — Splenic flexure — — — — — — — — — — — Descending colon 3 0.3 1 2 — 1 1 1 — — — Sigmoid colon 13 1.4 6 7 — 3 4 3 3 — — Large intestine, NOS 2 0.2 2 — — — — 1 1 — — Rectum and rectosigmoid junction 31 3.3 16 15 — 10 6 9 4 — 2 Rectosigmoid junction* 5 0.5 2 3 — 1 — 4 — — — Rectum 22 2.4 12 10 — 8 4 4 4 — 2 Anus, anal canal and anorectum 4 0.4 2 2 — 1 2 1 — — — Liver and intrahepatic bile duct 26 2.8 17 9 — 8 3 6 6 1 2 Liver 18 1.9 12 6 — 5 1 6 5 1 — Intrahepatic bile duct 3 0.3 2 1 — — 1 — — — 2 Gallbladder 2 0.2 — 2 — 1 — — 1 — — Other biliary 3 0.3 3 — — 2 1 — — — — Pancreas 26 2.8 15 11 — 2 7 4 11 — 2 Retroperitoneum — — — — — — — — — — — Peritoneum, omentum and mesentery — — — — — — — — — — — Other digestive organs 7 0.8 5 2 — — — — — 7 —RESPIRATORY SYSTEM 194 20.8 Nose, nasal cavity and middle ear — — — — — — — — — — — Larynx 3 0.3 3 — — 1 — — 2 — — Pleura — — — — — — — — — — — Lung and bronchus 191 20.5 100 91 — 57 28 35 70 — 1 Non–small cell 172 18.5 91 81 — 56 27 28 60 — 1 Small cell 14 1.5 6 8 — — 1 7 6 — — Other lung 5 0.5 3 2 — 1 — — 4 — — Trachea — — — — — — — — — — — Mediastinum and other respiratory — — — — — — — — — — —BONES AND JOINTS 2 0.2SOFT TISSUE INCLUDING HEART 2 0.2
Male Female 0 1 2 3 4 NA UNK SKIN 26 2.8 Melanoma of the skin 25 2.7 13 12 4 7 5 4 4 — 1
ASANTE ROGUE REGIONAL MEDICAL CENTERSITE, GENDER, AND COLLABORATIVE STAGE TABLE
933 Cases Diagnosed January 1-‐ December 31, 2014
NCI diagnosis group Total % Gender Collaborative stage group
Collaborative stage groupNCI diagnosis group Total %
Gender
Other non-‐epithelial skin 1 0.1 — 1 — — — 1 — — — Epithelial skin — — — — — — — — — — —BREAST 201 21.6 1 200 28 89 59 18 6 — 1 Female breast 200 21.5 — 200 28 89 59 17 6 — 1 Male breast 1 0.1 1 — — — — 1 — — —FEMALE GENITAL SYSTEM 40 4.3 Cervix uteri 7 0.8 — 7 — 5 1 1 — — — Corpus and uterus, NOS 21 2.3 — 21 1 16 — 1 2 — 1 Corpus uteri 21 2.3 — 21 1 16 — 1 2 — 1 Uterus, NOS — — — — — — — — — — — Ovary 7 0.8 — 7 — 2 1 2 1 — 1 Vagina — — — — — — — — — — — Vulva 3 0.3 — 3 1 2 — — — — — Other female genital organs 2 0.2 — 2 1 — — — — — —MALE GENITAL SYSTEM 54 5.8 Prostate 46 4.9 46 — — 8 27 2 8 — 1 Testis 7 0.8 7 — — 6 — 1 — — — Penis 1 0.1 1 — 1 — — — — — — Other male genital organs — — — — — — — — — — —URINARY SYSTEM 81 8.7 Urinary bladder 40 4.3 29 11 23 6 4 5 2 — — Kidney 32 3.4 24 8 — 20 2 3 6 — 1 Renal pelvis 5 0.5 3 2 1 1 — 1 1 — 1 Ureter 4 0.4 4 — 1 — — 1 1 — 1 Other urinary organs — — — — — — — — — — —EYE AND ORBIT — —BRAIN/OTHER NERVOUS SYSTEM 39 4.2 Brain, malignant 18 1.9 13 5 — — — — — 18 — Brain/CNS, benign and borderline — — — — — — — — — — — Cranial nerves other nervous system 21 2.3 8 13 — — — — — 21 —ENDOCRINE SYSTEM 24 2.6 Thyroid 18 1.9 8 10 — 7 1 3 4 — 3 Thymus — — — — — — — — — — — Adrenal gland 1 0.1 — 1 — — 1 — — — — Other endocrine — — — — — — — — — — — Endocrine, benign and borderline 5 0.5 3 2 — — — — — 5 —LYMPHOMA 37 4.0 Hodgkin's and lymphoma 4 0.4 4 — — — 2 1 1 — — Hodgkin's and nodal 4 0.4 4 — — — 2 1 1 — — Hodgkin's and extranodal — — — — — — — — — — — Non-‐Hodgkin's and lymphoma 33 3.5 20 13 — 4 8 5 15 1 — NHL — nodal 22 2.4 16 6 — 1 4 5 12 — — NHL — extranodal 11 1.2 4 7 — 3 4 — 3 1 —MYELOMA 8 0.9LEUKEMIA 9 1.0 Lymphocytic leukemia 4 0.4 2 2 — — — — — 3 1 Acute lymphocytic leukemia 1 0.1 — 1 — — — — — — 1 Chronic lymphocytic leukemia 3 0.3 2 1 — — — — — 3 — Other lymphocytic leukemia — — — — — — — — — — — Non-‐lymphocytic leukemia 5 0.5 4 1 — — — — — 5 — Acute myeloid leukemia 4 0.4 3 1 — — — — — 4 — Acute monocytic leukemia — — — — — — — — — — — Chronic myeloid leukemia 1 0.1 1 — — — — — — 1 — Other myeloid-‐monocytic leukemia — — — — — — — — — — — Other leukemia — — — — — — — — — — — Other acute leukemia — — — — — — — — — — — Aleukemic, subleukemic and NOS — — — — — — — — — — —MESOTHELIOMA 2 0.2KAPOSI SARCOMA — —OTHER 13 1.4TOTALS 932 100.0 429 503 61 268 176 134 184 84 25
*One additional rectosigmoid case (Stage 2) not coded in the table due to transsexual status.
Male Female 0 1 2 3 4 NA UNK
ORAL CAVITY AND PHARYNX 27 2.9 Lip — — — — — — — — — — — Tongue 10 1.1 7 3 — 2 1 — 7 — — Salivary gland 6 0.6 5 1 — — 1 1 4 — — Floor of mouth — — — — — — — — — — — Gum and other mouth 2 0.2 1 1 — — — — 1 — 1 Nasopharynx 5 0.5 4 1 — — 1 — 4 — — Tonsil 1 0.1 1 — — — — 1 — — — Oropharynx 2 0.2 1 1 — — — — 1 — 1 Hypopharynx 1 0.1 1 — — — — 1 — — — Other oral cavity and pharynx — — — — — — — — — — —DIGESTIVE SYSTEM 173 18.6 Esophagus 11 1.2 9 2 — 4 — 2 4 — 1 Stomach 14 1.5 7 7 — 2 1 4 4 — 3 Small intestine 2 0.2 1 1 — — — 1 1 — — Colon and rectum 87 9.3 43 44 — 18 21 30 16 — 2 Colon excluding rectum 56 6.0 27 29 — 8 15 21 12 — — Cecum 8 0.9 3 5 — 1 1 5 1 — — Appendix 3 0.3 3 — — — 1 — 2 — — Ascending colon 10 1.1 3 7 — 1 3 3 3 — — Hepatic flexure 3 0.3 2 1 — — — 3 — — — Transverse colon 14 1.5 7 7 — 2 5 5 2 — — Splenic flexure — — — — — — — — — — — Descending colon 3 0.3 1 2 — 1 1 1 — — — Sigmoid colon 13 1.4 6 7 — 3 4 3 3 — — Large intestine, NOS 2 0.2 2 — — — — 1 1 — — Rectum and rectosigmoid junction 31 3.3 16 15 — 10 6 9 4 — 2 Rectosigmoid junction* 5 0.5 2 3 — 1 — 4 — — — Rectum 22 2.4 12 10 — 8 4 4 4 — 2 Anus, anal canal and anorectum 4 0.4 2 2 — 1 2 1 — — — Liver and intrahepatic bile duct 26 2.8 17 9 — 8 3 6 6 1 2 Liver 18 1.9 12 6 — 5 1 6 5 1 — Intrahepatic bile duct 3 0.3 2 1 — — 1 — — — 2 Gallbladder 2 0.2 — 2 — 1 — — 1 — — Other biliary 3 0.3 3 — — 2 1 — — — — Pancreas 26 2.8 15 11 — 2 7 4 11 — 2 Retroperitoneum — — — — — — — — — — — Peritoneum, omentum and mesentery — — — — — — — — — — — Other digestive organs 7 0.8 5 2 — — — — — 7 —RESPIRATORY SYSTEM 194 20.8 Nose, nasal cavity and middle ear — — — — — — — — — — — Larynx 3 0.3 3 — — 1 — — 2 — — Pleura — — — — — — — — — — — Lung and bronchus 191 20.5 100 91 — 57 28 35 70 — 1 Non–small cell 172 18.5 91 81 — 56 27 28 60 — 1 Small cell 14 1.5 6 8 — — 1 7 6 — — Other lung 5 0.5 3 2 — 1 — — 4 — — Trachea — — — — — — — — — — — Mediastinum and other respiratory — — — — — — — — — — —BONES AND JOINTS 2 0.2SOFT TISSUE INCLUDING HEART 2 0.2
Male Female 0 1 2 3 4 NA UNK SKIN 26 2.8 Melanoma of the skin 25 2.7 13 12 4 7 5 4 4 — 1
ASANTE ROGUE REGIONAL MEDICAL CENTERSITE, GENDER, AND COLLABORATIVE STAGE TABLE
933 Cases Diagnosed January 1-‐ December 31, 2014
NCI diagnosis group Total % Gender Collaborative stage group
Collaborative stage groupNCI diagnosis group Total %
Gender
Multidisciplinary cancer conferences
Number of conferences held in 2014 . . . . . . . . . . . . . . . . . . . . . . . . 44 Average physician attendance per conference . . . . . . . . . . . . . . . . 16 Average ancillary staff attendance per conference . . . . . . . . . . . . . 6Number of cases presented . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164 Prospective cases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 Retrospective cases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314
Asante Rogue Regional and Providence Medford Medical Center hold multidisciplinary cancer conferences jointly to provide consultative services to cancer patients in the Rogue Valley. Cancer Registry personnel support these conferences by maintaining required documentation, gathering imaging and pathology information and handling equipment and room arrangements. Medical staff physician representatives from surgery,
medical oncology, radiation oncology, gynecologic oncology, diagnostic radiology, pathology and other specialties attend and participate in the conferences. Ancillary staff regularly attend as well, representing social services, oncology nursing, radiation oncology, clinical trials, imaging and the Cancer Registry. Quality of patient care is continuously improved with discussion of American Joint Committee on Cancer stage and national guidelines.
Cancer patient support services
Breast health/oncology navigatorsOur nurse navigators guide patients through treatment and follow-up. They answer questions and offer emotional support every step of the way, as well as coordinate visits for the cancer care team. They also promote cancer screenings and education to patients and their families.
Social Work ServicesOur social workers assist cancer patients in both the inpatient and outpatient settings. They provide information to cancer patients and their families about available resources, including financial assistance. They also offer valuable support to patients and their loved ones to help them cope with distress related to a cancer diagnosis and treatment.
Nutritional ServicesOur dietitians provide patients with individualized nutritional care in both the inpatient and outpatient settings. They work closely with each patient’s health care team to provide comprehensive care, with the goals of keeping patients strong, maintaining muscle mass, promoting healing, treating nutritional deficiencies and minimizing complications from disease or treatment.
Patient Financial ServicesWe offer financial counselors to help patients navigate insurance programs and understand the costs of cancer treatment. We also have programs that help patients secure medications and other treatments at reduced or no cost.
Educational resourcesOur cancer resource center is located in the Dubs cancer building. There are many resource materials available to patients at no cost.
Cancer research and clinical trialsOur cancer research team has access to multiple clinical trials and continually updates the list of trials that are available. The team works closely with both medical and radiation oncologists.
Genetic counselingThrough our telemedicine genetics clinic and consultations, we are better able to understand the underlying cause of disease, allowing us to design highly individualized treatment plans. Full risk assessments along with genetic testing may also give families more information about potential increased risk for individual family members.
Palliative careOur inpatient palliative care team provides a second layer of support for patients dealing with a serious disease. This team focuses on quality of life and addresses patients’ medical, emotional and spiritual needs.
Asante Rehabilitation ServicesWe provide a wide range of cancer rehabilitation services, such as physical therapy, lymphedema services, speech and swallow therapy and occupational therapy, to help restore functional abilities for patients experiencing side effects of disease and treatment.
Support groupsOur cancer program staff facilitates support groups and educational programs for patients and families affected by gynecological, breast and blood cancers. Patients and families learn about community cancer support groups and agencies that provide practical and emotional support. We also collaborate with national cancer programs such as Look Good Feel Better, sponsored in part by the American Cancer Society.
15
16ONCR002
© 2016 Asante. All rights reserved. No part of this publication may be reproduced in any form except by prior written permission.
asante.org
